Follow-up of NAFLD Patients With MRI-PDFF

Inclusion Criteria: * Patients who are willing to participate in this study * Adults aged ≥ 18 years old presented at the clinic with a confirmed diagnosis of T2DM who are on sulfonylurea for the last 6 months at least and diagnosed with NAFLD. Exclusion Criteria: * • Patients who refused to participate in this trial * Patients diagnosed with Type 1 diabetes * Previous history of alcohol intake * history of recurrent attacks of ketoacidosis in a diabetic patient * Type 2 diabetic patient with kidney dysfunction (estimated eGFR below 60ml/min/1.73m2 or CrCl below 60ml/min) or on dialysis * Previous history of taking medication that may alter either drug efficacy (eg, corticosteroids, oral contraceptives, and thiazide diuretics) * Evidence of another liver disease (viral hepatitis, drug-induced liver disease, autoimmune hepatitis) * Lactating/pregnant female or children ≤ 18 * Any contraindication for Empagliflozin including: 1. History of recurrent attacks of UTI or Genital infection in females 2. History of recurrent foot injuries or infections 3. Type 2 diabetic patient with CV disease especially NYHA classes III/ IV 4. Immunocompromised patients or with a history of inflammatory, immunological, or malignant diseases. * Any contraindication for PTX including: 1. Hypersensitivity to PTX 2. Patients with peptic ulcer disease or tendency for bleeding * Any contraindication for UDCA including: 1. Hypersensitivity to UDCA 2. Patients with biliary disease or hepatobiliary disease (ascites, jaundice) 3. Patients with hepatic encephalopathy or gallstone pancreatitis